



S 2101

Catalog No: tcsc0033145



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg



Specifications

CAS No:

1239262-36-2

Formula:

 $\mathsf{C_{16}H_{16}CIF_2NO}$

Pathway:

Epigenetics

Target:

Histone Demethylase

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

311.75

Product Description

S 2101 is a **lysine-specific demethylase 1** (**LSD1**) inhibitor with an IC_{50} of 0.99 μ M, K_i of 0.61 μ M and K_{inact}/K_i of 4560 M/s.

IC50 & Target: IC50: 0.99 μM (LSD1)^[1]





Ki: $0.61 \, \mu M \, (LSD1)^{[1]}$

In Vitro: S 2101 is a lysine-specific demethylase 1 (LSD1) inhibitor with an IC $_{50}$ of 0.99 μ M, K $_i$ of 0.61 μ M and K $_{inact}$ /K $_i$ of 4560 M/s. S 2101 also displays much lower inhibition activity toward MAO-B (K $_i$ =17 μ M, K $_{inact}$ /K $_i$ =18 M/s) and MAO-A (K $_i$ =110 μ M, K $_{inact}$ /K $_i$ =60 M/s). The treatment of HEK293T cells with S 2101 results in a dose-dependent increase in the level of H3K4me2, which must have accumulated by the inactivation of LSD1. During the course of S 2101 treatment, the amounts of histone H3 and LSD1 in the nuclear extracts remain essentially unaffected. Because the treatment with 1 μ M S 2101 generates a level of H3K4me2 similar to that elicited by 50 μ M 2-PCPA, S 2101 is assumed to have approximately 50-fold stronger LSD1 inhibition activity than 2-PCPA in human cells^[1].

$$H_2N^{W}$$
 F
 HCI

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!